GBM represents a lower cost cancer type to prove the safety and...

GBM represents a lower cost cancer type to prove the safety and efficacy of the therapy in clinical trials. The less prevalent a disease, the smaller the trials. It really is only the large cap bios that can afford to consider trialing drugs (esp Car-T) for those common cancers that represent bigger commercial markets. Targeting indications of low of unmet need is a way of proving the mechanism of action in humans which can then be applied to broader cancer types and getting them undertaken in combo therapies in partnership with Big Pharma.

The other point that perhaps you are missing (or trying to pry out) is the fact that whilst the market of GBM is small in terms of patient numbers, it is a lucrative one. Patient treatments command much higher prices for rare diseases - they have to otherwide no drugs would ever be developed or commercialised to fill the void. Big Pharma tend to go after the larger patient cancer types (ie the most prevalent). The areas of unmet need is where small biotech companies such as CHM can feasibly get a drug to market or at least get a drug or therapy developed and recognised as applied to other types of cancer.

I agree with the essence of what you are saying and, that is (I think), posters are focusing on the discussion of GBM because it is perceived as horrific and incurable. CHM has quite a vast pipeline of interesting therapies as it turns out, and I'm sure investors (who are more than likely also traders) are cognisant of the full portfolio of programs CHM has on the go. Besides, I don't think many are invested solely in a cure for GBM. In fact, its pretty clear that immunotherapy is a blockbuster cure for all cancers but ultimately represents the alternate therapy to chemotherapy. Personalised (precision) medicine is what immunotherapy will offer cancer patients - the best of the best combination of therapies available within their country, city or local region. Biotechs simply research and develop new and innovative therapies in the hope that they pose potential towards commercialisation. That can be achieved either via their own volition in taking advantage of govt incentives such as ODD and fast-track registration trials or via collabs, partnerships or takeovers.